These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 34467623)
21. Immunogenicity and safety of two doses of SARS-CoV-2 mRNA vaccine in kidney transplant recipients with low-dose rituximab. Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N Int J Urol; 2022 Nov; 29(11):1279-1286. PubMed ID: 35863901 [TBL] [Abstract][Full Text] [Related]
22. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients. Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N Front Immunol; 2022; 13():1050211. PubMed ID: 36532067 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of SARS-CoV-2 Vaccine in Kidney Transplant Recipients: A Cross-Sectional Study in Korea. Song SH; Chung KY; Jee Y; Chung HS; Kim K; Minn D; Kim SK J Korean Med Sci; 2023 Feb; 38(5):e22. PubMed ID: 36747360 [TBL] [Abstract][Full Text] [Related]
24. Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response. Midtvedt K; Vaage JT; Heldal K; Munthe LA; Lund-Johansen F; Åsberg A Am J Transplant; 2022 Nov; 22(11):2704-2706. PubMed ID: 35533010 [No Abstract] [Full Text] [Related]
25. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083 [TBL] [Abstract][Full Text] [Related]
26. Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19. Benotmane I; Risch S; Doderer-Lang C; Caillard S; Fafi-Kremer S Am J Transplant; 2021 Aug; 21(8):2871-2875. PubMed ID: 33961334 [TBL] [Abstract][Full Text] [Related]
27. Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. Herrera S; Colmenero J; Pascal M; Escobedo M; Castel MA; Sole-González E; Palou E; Egri N; Ruiz P; Mosquera M; Moreno A; Juan M; Vilella A; Soriano A; Farrero M; Bodro M Am J Transplant; 2021 Dec; 21(12):3971-3979. PubMed ID: 34291552 [TBL] [Abstract][Full Text] [Related]
29. Persistence of SARS-CoV-2 antibodies in kidney transplant recipients. Benotmane I; Gautier Vargas G; Velay A; Wendling MJ; Perrin P; Fafi-Kremer S; Caillard S Am J Transplant; 2021 Jun; 21(6):2307-2310. PubMed ID: 33370503 [No Abstract] [Full Text] [Related]
30. Response to Third Dose of Vaccine Against SARS-CoV-2 in Adolescent and Young Adult Kidney Transplant Recipients. Cirillo L; Citera F; Mazzierli T; Becherucci F; Terlizzi V; Lodi L; Buti E; Romagnani P Transplantation; 2022 Aug; 106(8):e386-e387. PubMed ID: 35581690 [No Abstract] [Full Text] [Related]
31. Delayed kinetics of SARS-CoV-2 IgG antibody production in kidney transplant recipients following the third dose of COVID-19 vaccination. Matsunami M; Suzuki T; Yashima J; Kuji H; Matsue K Clin Exp Nephrol; 2023 Jan; 27(1):98-99. PubMed ID: 35931918 [No Abstract] [Full Text] [Related]
32. True effect of monoclonal antibody for COVID-19 in kidney transplant recipients. Khatri A; Raja M; Guerra G; Natori Y Am J Transplant; 2022 May; 22(5):1492-1493. PubMed ID: 34897967 [No Abstract] [Full Text] [Related]
33. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients. Haller MC; Kaiser RA; Langthaler S; Brandstetter C; Apfalter P; Kerschner H; Cejka D Transpl Int; 2021; 35():10026. PubMed ID: 35185359 [No Abstract] [Full Text] [Related]
34. Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients. Tunbridge M; Perkins GB; Singer J; Salehi T; Ying T; Grubor-Bauk B; Barry S; Sim B; Hissaria P; Chadban SJ; Coates PT Trials; 2022 Sep; 23(1):780. PubMed ID: 36109788 [TBL] [Abstract][Full Text] [Related]
35. Humoral Response After SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Role of Immunosuppression Therapy. López V; Polo C; Schuldt R; Vázquez T; Gutiérrez-Vílchez E; Moliz C; Hernández D Transplant Proc; 2022 Nov; 54(9):2454-2456. PubMed ID: 36273957 [TBL] [Abstract][Full Text] [Related]
36. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273 [TBL] [Abstract][Full Text] [Related]
37. Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients. Grupper A; Rabinowich L; Ben-Yehoyada M; Katchman E; Baruch R; Freund T; Hagin D; Shlomo SB; Schwartz D; Schwartz IF; Shashar M; Bassat OK; Halperin T; Turner D; Saiag E; Goykhman Y; Shibolet O; Levy S; Houri I; Katchman H Transplant Proc; 2022; 54(6):1439-1445. PubMed ID: 35346486 [TBL] [Abstract][Full Text] [Related]
38. Immune Response to Third and Fourth COVID-19 Vaccination in Hemodialysis Patients and Kidney Transplant Recipients. Affeldt P; Koehler FC; Brensing KA; Gies M; Platen E; Adam V; Butt L; Grundmann F; Heger E; Hinrichs S; Kalisch N; Oehm S; Steger G; Wirtz M; Benzing T; Stippel D; Klein F; Kurschat C; Müller RU; Di Cristanziano V Viruses; 2022 Nov; 14(12):. PubMed ID: 36560648 [TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 Vaccine Mandates for Patients on the Kidney Transplant Waitlist: Are They Ethical? Tallaa F; Gunaratnam L; Suri RS Clin J Am Soc Nephrol; 2022 May; 17(5):746-748. PubMed ID: 35236716 [No Abstract] [Full Text] [Related]
40. Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin - study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients. Singer J; Tunbridge M; Perkins GB; Salehi T; Ying T; Wu H; Coates PT; Chadban SJ BMJ Open; 2022 Dec; 12(12):e062747. PubMed ID: 36456021 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]